Market Place
Sourcing Support
Essa drops lead cancer drug after falling short against Xtandi
04 Nov 2024 //
FIERCE BIOTECH
Essa drops lead cancer drug after falling short against Xtandi
01 Nov 2024 //
FIERCE BIOTECH
Essa Pharma Terminates Ph 2 Study of Masofaniten in Prostate Cancer
31 Oct 2024 //
PR NEWSWIRE
ESSA Pharma Presents Updated Masofaniten Clinical Data At ESMO 2024
13 Sep 2024 //
PR NEWSWIRE
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
11 Sep 2024 //
PR NEWSWIRE
ESSA Pharma Reports Q3 2024 Financial Results And Updates
05 Aug 2024 //
PR NEWSWIRE
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
08 Jul 2024 //
PR NEWSWIRE
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
PR NEWSWIRE
ESSA Pharma Provides Update, Fiscal Q2 2024 Financial Results
14 May 2024 //
PR NEWSWIRE
ESSA Pharma At Bloom Burton Healthcare Investor Conf 2024
09 Apr 2024 //
PR NEWSWIRE
Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders
07 Mar 2024 //
PR NEWSWIRE
ESSA Pharma Provides Financial Results for Fiscal Q1 Ended December 31, 2023
13 Feb 2024 //
PR NEWSWIRE
ESSA Pharma to Present at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
PR NEWSWIRE
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
25 Jan 2024 //
PR NEWSWIRE
ESSA Pharma Reports Financial Results for Fiscal Fourth Quarter
12 Dec 2023 //
PR NEWSWIRE
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
PR NEWSWIRE
ESSA Pharma to Present at the Jefferies London Healthcare Conference
08 Nov 2023 //
PR NEWSWIRE
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
06 Nov 2023 //
PR NEWSWIRE
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
26 Oct 2023 //
PR NEWSWIRE
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
21 Oct 2023 //
PR NEWSWIRE
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten
18 Sep 2023 //
PR NEWSWIRE
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
31 Aug 2023 //
PR NEWSWIRE
ESSA Pharma Reports Financial Results for Fiscal Third Quarter
08 Aug 2023 //
PR NEWSWIRE
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
06 Jun 2023 //
PR NEWSWIRE
ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
01 Jun 2023 //
PR NEWSWIRE
ESSA Pharma to Present at JMP Securities Life Sciences Conference
11 May 2023 //
PR NEWSWIRE
ESSA Pharma Provides Corporate Update FYR for Fiscal 2nd Q Ended March 2023
09 May 2023 //
PR NEWSWIRE
ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Conference
18 Apr 2023 //
PR NEWSWIRE
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 Mar 2023 //
PR NEWSWIRE
ESSA Pharma Announces Presentations at the ASCO GU
13 Feb 2023 //
PR NEWSWIRE
ESSA Pharma Reports Financial Results for Fiscal Q1
07 Feb 2023 //
PR NEWSWIRE
ESSA Pharma to Participate in the Guggenheim Healthcare Talks Conference
02 Feb 2023 //
PR NEWSWIRE
ESSA PharmaReports Financial Results for Fiscal Fourth Quarter
13 Dec 2022 //
PRNEWSWIRE
ESSA Pharma to Participate in Two Upcoming Investor Conferences
10 Nov 2022 //
PRNEWSWIRE
ESSA Pharma Presents Data for Androgen Receptor N-Terminal Domain Degrader
26 Oct 2022 //
PRNEWSWIRE
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
13 Sep 2022 //
PRNEWSWIRE
ESSA Pharma Reports Financial Results for Fiscal Q3 Ended June 30, 2022
04 Aug 2022 //
PRNEWSWIRE
ESSA Pharma Presents Clinical Update on EPI-7386 Mono and Combination Therapy
27 Jun 2022 //
PRNEWSWIRE
ESSA Pharma to Present at 2022 Jefferies Healthcare Conference
02 Jun 2022 //
PRNEWSWIRE
ESSA Pharma Reports Financial Results for Fiscal Q2 Ended March 31, 2022
10 May 2022 //
PRNEWSWIRE
ESSA Pharma to Present at the 2022 Bloom Burton & Co. Investor Conference
26 Apr 2022 //
PRNEWSWIRE
ESSA to present PC Data on 1st Gen Androgen Receptor N-Terminal Domain Degraders
08 Apr 2022 //
PRNEWSWIRE
ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference
10 Mar 2022 //
PRNEWSWIRE
Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders
09 Mar 2022 //
PRNEWSWIRE
ESSA to Show PC Data for First Gen Androgen Receptor N-Terminal Domain Degraders
08 Mar 2022 //
PRNEWSWIRE
ESSA Pharma Provides Corporate Update and Reports Financial Results
03 Feb 2022 //
PRNEWSWIRE
ESSA Pharma Begins Dosing in Phase 1/2 Clinical Trial of EPI-7386
19 Jan 2022 //
PRNEWSWIRE
ESSA Pharma Provides Corporate Update and Reports Financial Results
18 Nov 2021 //
PRNEWSWIRE
ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific
28 Oct 2021 //
PRNEWSWIRE
Metrics Contract Services Signs Development & Manufacturing Agreement with ESSA
08 Oct 2021 //
CONTRACTPHARMA
Caris Life, ESSA Pharma ink liquid biopsy profiling collaboration
08 Oct 2021 //
PHARMABIZ
ESSA rises ~5% amid preclinical data show for prostate cancer drug
07 Oct 2021 //
SEEKINGALPHA
Metrics Contract to assist ESSA on oral oncology drug development
07 Oct 2021 //
MANUFACTURINGCHEMIST
Caris Life Sciences & ESSA Pharma Announce Liquid Biopsy Profiling Collaboration
07 Oct 2021 //
PRNEWSWIRE
ESSA Pharma Announces the Presentation of Preclinical Data of EPI-7386
07 Oct 2021 //
PRNEWSWIRE
ESSA Pharma to Present at Upcoming September Investor Conferences
31 Aug 2021 //
PRNEWSWIRE
ESSA Phar gains 8% as owner buys more shares
23 Aug 2021 //
SEEKINGALPFA
ESSA Pharma Provides Corporate Update and Reports Financial Results
16 Aug 2021 //
PRNEWSWIRE
ESSA Pharma Announces Clinical Collaboration Agreement with Bayer
28 Apr 2021 //
PRNEWSWIRE
ESSA Pharma Announces Clinical Collaboration Agreement with Bayer
28 Apr 2021 //
PRNEWSWIRE
